Summary
This application note demonstrates how LunaX™ ECM reveals breast cancer subtype-specific responses to Abraxane that conventional 2D assays miss. In 3D culture, compact MCF-7 spheroids showed greater resistance, while metastatic MDA-MB-231 cells remained sensitive, producing a response pattern consistent with clinical observations.
What you’ll learn
- How to compare Abraxane response in MCF-7 and MDA-MB-231 breast cancer cells using parallel 2D and 3D assays.
- How to model physiological-like and tumour-like breast tissue stiffness with 3 kPa and 10 kPa LunaX ECMs.
- Why compact 3D spheroid architecture can reduce drug penetration and alter apparent treatment sensitivity.
- How epithelial MCF-7 and mesenchymal MDA-MB-231 cells adopt distinct growth morphologies in 3D ECM.
- How a mechanistically tunable 3D model can improve subtype-specific drug-response screening and compound progression decisions.
Key findings
- In 2D monolayers, both breast cancer cell lines appeared sensitive to Abraxane, providing little ability to distinguish subtype-specific responses.
- MCF-7 cells formed compact, well-structured spheroids in LunaX ECM and retained substantially more metabolic activity and viability after treatment than in 2D.
- MDA-MB-231 cells grew as dispersed cells or loose clusters and showed more than 50% loss of viability after Abraxane treatment in both 2D and 3D conditions.
- The contrasting 3D responses reproduced the clinically relevant pattern of greater Abraxane sensitivity in metastatic disease than in compact primary tumour models.
- LunaX ECM enabled breast cancer drug response to be tested reproducibly at both 3 kPa physiological-like stiffness and 10 kPa tumour-like stiffness.
